Sanjiv Sam Gambhir, MD, PhD

Publication Details

• Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.

  Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, Chen X. J Nucl Med. 2006; 47 (1): 113-21

  The development of noninvasive methods to visualize and quantify integrin alpha(v)beta(3) expression in vivo appears to be crucial for the success of antiangiogenic therapy based on integrin antagonism. Precise documentation of integrin receptor levels will allow appropriate selection of patients who will most likely benefit from an antiintegrin treatment regimen. Imaging can also be used to provide an optimal dosage and time course for treatment based on receptor occupancy studies. In addition, imaging integrin expression will be important to evaluate antiintegrin treatment efficacy and to develop new therapeutic drugs with favorable tumor targeting and in vivo kinetics. We labeled the dimeric RGD peptide E[c(RGDyK)](2) with (18)F and evaluated its tumor-targeting efficacy and pharmacokinetics of (18)F-FB-E[c(RGDyK)](2) ((18)F-FRGD2).

  PubMedID: 16391195